PET/MRI评估非小细胞肺癌肿瘤可切除性的价值:与PET/CT的个体内比较
本研究对36例临床需评估可切除性的非小细胞肺癌患者行序贯PET/CT/MRI三模态检查,比较PET/MRI与PET/CT判断肿瘤可切除性的诊断准确性。结果显示两者在肿瘤最大径、可切除性定义因素上一致性高,T2-Propeller序列与CT对额外肺结节检出的一致性极好,T1-Dixon序列一致性中等至良好;作者认为PET/MRI可提供与PET/CT相当的诊断价值,并建议全身PET/MRI可安全用于NSCLC局部分期,但需进一步研究。
要点
- PET/MRI与PET/CT判断NSCLC可切除性的一致性高(k 0.769~1.000)。
- T2-Propeller序列与CT检出额外肺结节的k值分别为0.829和0.833,一致性极好。
- T1-Dixon序列检出额外肺结节的一致性仅中等至良好(k 0.484和0.722)。
核心结论
- 在非小细胞肺癌中,使用包含专用肺部MR成像方案的PET/MRI,对肿瘤可切除性的判断可提供与PET/CT相当的诊断价值。
研究设计与样本
- 个体内比较研究,36例临床需评估可切除性的非小细胞肺癌患者接受序贯PET/CT/MRI三模态检查,评估PET/CT与PET/MR图像(包括T1加权序列T1-Dixon和呼吸门控T2加权序列T2-Propeller)。
关键影像表现/征象
- PET/MRI与PET/CT在肿瘤最大径测量上无显著差异,Bland-Altman分析一致性界限窄:T2-Propeller序列为-11.1 mm至+11.8 mm,T1-Dixon序列为-14.3 mm至+13.8 mm。
- PET/MR与PET/CT在各可切除性定义因素上一致性高(k 0.769至1.000)。
- T2-Propeller序列与CT检出额外肺结节的一致性极好(k分别为0.829和0.833),T1-Dixon序列仅中等至良好(k分别为0.484和0.722)。
诊断标准与关键数值
- 可切除性定义因素包括:肿瘤最长径、肿瘤至隆突最小距离、纵隔侵犯、隆突侵犯、胸膜浸润、心包浸润、膈肌浸润、额外结节存在。
- PET/MR与PET/CT在各可切除性定义因素上的一致性k值为0.769至1.000。
- T2-Propeller序列与CT检出额外肺结节的k值分别为0.829和0.833;T1-Dixon序列分别为0.484和0.722。
临床应用与阅片要点
- 作者认为,全身PET/MRI可安全用于非小细胞肺癌患者的局部分期。
- 作者指出,需进一步研究以确定在全身PET/MRI方案中整合一个成像序列是否可行,该序列可能具有检出肝或脑转移的优势。
局限性
- 作者指出,需进一步研究以确定在全身PET/MRI方案中整合一个成像序列是否可行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this study was to compare the diagnostic accuracy of positron emission tomography (PET)/MRI with PET/CT for determining tumor resectability of non-small cell lung cancer (NSCLC).
METHODS: Sequential trimodality PET/CT/MRI was performed in 36 patients referred with the clinical question of resectability assessment in NSCLC. PET/CT and PET/MR images including T1 weighted sequence (T1-Dixon) and respiration gated T2 weighted sequence (T2-Propeller) were evaluated for resectability-defining factors; i.e. longest diameter of the tumor, minimal tumor distance to the carina, mediastinal invasion, invasion of the carina, pleural infiltration, pericardial infiltration, diaphragm infiltration, presence of additional nodules.
RESULTS: There was no significant difference of maximal axial diameter measurements of the primary lung tumors and narrow limits of agreement in Bland-Altman analysis ranging from -11.1 mm to + 11.8 mm for T2-Propeller and from -14.3 mm to + 13.8 mm for T1-Dixon sequence. A high agreement of PET/MR with PET/CT for the different resectability-defining factors was observed (k from 0.769 to 1.000). There was an excellent agreement of T2-Propeller sequence and CT for additional pulmonary nodule detection (k of 0.829 and 0.833), but only a moderate and good agreement using T1-Dixon sequence (k of 0.484 and 0.722).
CONCLUSION: In NSCLC the use of PET/MRI, including a dedicated pulmonary MR imaging protocol, provides a comparable diagnostic value for determination of tumor resectability compared to PET/CT.
ADVANCES IN KNOWLEDGE: Our findings suggest that whole body PET/MRI can safely be used for the local staging of NSCLC patients. Further studies are warranted to determine whether it is feasible to integrate an imaging sequence in a whole body PET/MRI setting with the potential advantage of detection of liver or brain metastases.
引用
- Messerli M, de Galiza Barbosa F, Marcon M, et al. Value of PET/MRI for assessing tumor resectability in NSCLC-intra-individual comparison with PET/CT. Br J Radiol. 2018. PMID: 30209954. doi:10.1259/bjr.20180379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。